Sistemic Announces Customer Agreement with Cytori Therapeutics

Cytori to Utilize Sistemic’s SistemQC™ to Strengthen Understanding of  Mechanisms & Support Design of Next-Generation Cell Therapies Boston, Mass., USA, June 20, 2012 / B3C newswire / – Sistemic Ltd. (“Sistemic”), a leading provider of microRNA-based problem-solving services and kit-based products, has formed a customer relationship with Cytori Therapeutics (“Cytori”). Cytori will utilize Sistemic’s proprietarySistemQC™  technology platform in its U.S. cardiac cell therapy clinical trial to molecularly characterize adipose-derived stem and regenerative cells (ADRCs). “Research has shown that within adipose tissue, as well as other cell sources like bone marrow, there are multiple distinct cell types that can contribute to efficacy,” commented Sistemic chairman and CEO Jim Reid. “Cytori selecting our SistemQC serves as another validation of our technology, particularly its flexibility to characterize a wide variety of cells for identity and potency, on a molecular level. We could not be more pleased to have reached this agreement with Cytori.” The announcement was made at the 2012 Bio International Convention in Boston, where Mr. Reid is moderating a panel on stem cell therapeutics featuring leaders from the industry, on Wednesday, June 20, at the Boston Convention Center. “SistemQC will be incorporated into our clinical development to understand which cell types within our Celution® System’s autologous heterogeneous population of ADRCs are the greatest contributors to efficacy,” said Douglas Arm, Ph.D., Senior Vice President Operations at Cytori. “With Sistemic’s novel technology, we can strengthen the mechanistic understanding of our cell output and at the same time support the design of next-generation cell therapies.” About Sistemic Ltd Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™. About Cytori Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family. Contact Dr. Verna McErlane Director of Commercial Operations + 44 (0)7855 376 358 verna.mcerlane@sistemic.co.uk

Sistemic to Moderate Regenerative Medicine Panel at 2012 Bio International Convention

“Stem Cell Therapies… Fact or Fiction” to be Moderated by CEO Jim Reid and Feature C-Suite Executives from California Stem Cell, Tigenix, and Angel Biotechnology

 Boston, Mass. – June 18, 2012 – Sistemic Ltd., a leading provider of microRNA-based problem-solving services and kit-based products to the Cell Therapy community, announced today that chairman and CEO Jim Reid is moderating a panel discussion at the 2012 Bio International Convention on Wednesday, June 20, in Boston. Featuring leaders from the regenerative medicine space, the panel is titled “Stem Cell Therapies… Fact or Fiction,” and will share the lessons learned to-date from  Scottish, European and American perspectives on the path to successful commercialization of stem cell therapies.

Jim Reid, Sistemic CEO, commented, "Sistemic is very active in the Cell Therapy arena and are members of Alliance for Advanced Therapies (AAT) and the Alliance for Regenerative Medicine (ARM). We see the ability to raise this topic at the leading world event, BIO 2012, as an important step on the path to commercialization of these products which will be transformational in healthcare, and bring hope and cures to many people around the globe."

 More information on the panel at BIO 2012:

What: Panel Discussion Featuring Leaders in the Regenerative Medicine Space

When: Wednesday, June 20, 3:00PM EDT

Where: Boston Convention Center, Room 254A

Who: Leaders of the Regenerative Medicine space:

• ·         Jim Reid, Chairman and CEO, Sistemic, UK & USA
• ·         Chief Operating Officer, California Stem Cell, USA
• ·         Eduardo Bravo, CEO, Tigenix, Belgium & Spain
• ·         Stewart White, Commercial Director and acting CEO, Angel Biotechnology Plc, UK

Panel objectives include evaluating lessons learned and best practice including  from the Scotland Roadmap for the commercialization of stem cell therapies; identifying global (US and EU) examples of progress in stem cell therapy commercialization; and facilitating a debate on the need for a global, multi-disciplinary approach to successful commercialization of stem cell therapies.

About Sistemic Ltd

Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™. 

More information is available at http://www.sistemic.co.uk

Contact:

 Dr. Verna McErlane

Director of Commercial Operations

+ 44 (0)7855 376 358

verna.mcerlane@sistemic.co.uk

Successful trade mission to Japan and Korea yields new business opportunities for Sistemic

26 March 2012: Sistemic, UK:  Sistemic Ltd, Glasgow, concluded a successful trade mission to Japan and Korea in February 2012. Verna McErlane, Director of Commercial Operations, presented the company’s miRNA-based approach to a receptive group of businesses and research institutions in Tokyo, Osaka, Kyoto, Seoul and Jeonju. The Japan portion of the trip was planned by the Scottish and Japanese offices of Scottish Development International (SDI).

 During the visit, Sistemic met with both existing and potential clients, and participated in a number of seminars and partnering sessions. Verna McErlane, Director of Commercial Operations, Sistemic, explained: “As the trade mission progressed, it became clear that the partnership model for drug development features highly in the plans of the pharma industry there. It was exciting to have the chance to present how the world’s second largest pharma market will benefit from Sistemic’s unique miRNA profiling products and services.”

Sistemic is pursuing an active global expansion plan for the business. Jim Reid, Sistemic’s CEO commented: “Pharma companies are looking to access technologies on a global basis, so it’s important Sistemic is recognised at this level. We are proud to have customers all over the US and Europe, as well as in Australia and Asia Pacific and we look forward to working closely with a number of new partners in Japan and Korea as a result of the trade mission.”

 During the visit, Sistemic presented its SistemQC product for use in cell characterisation and QC. This is of particular interest to anyone working on cell therapies, regenerative medicine and stem cells. SistemQC is a miRNA-based fingerprint approach that provides a powerful and informative way to characterise and monitor cells lines, including stem cells, for identity, purity, safety and differentiation staging. Sistemic also presented details of SistemRNA and how it is used in drug discovery and development. SistemRNA applies a compound-centric approach identifying drug effects by associative changes in miRNA express profiles and its analysis in context. The addition of SistemRNA to the drug discovery toolbox can support strategic decision-making at key stages and maximise asset value.

Verna McErlane added: “The people we met in both countries were very welcoming and interested in innovative tools that can help them in their work. We are following up with a number of companies and planning return visits in June and September.”

For more information about Sistemic and it's products and services, visit: www.sistemic.co.uk